As demand for GLP-1 receptor agonists (GLP-1RAs) surges, fragmented prescribing practices threaten patient safety. A coordinated response from regulators, prescribers and patients is urgently needed to facilitate the ongoing monitoring of the safety of these products.
Media coverage of GLP-1RAs for weight management has intensified, reflecting both growing public interest and the expanding clinical relevance of these therapies.
Originally developed for type 2 diabetes, GLP-1RAs are now widely used for the extended indication of weight loss, often accessed through online platforms that bypass National Health Service (NHS) care pathways.
Check out the rest of the feature here
